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and Cellular and Molecular Biology
ABSTRACT: Epilepsy is the most common neurological disorder. The term epilepsy serves as

an umbrella term to describe any faulty mechanism in the brain that causes an electrical storm,
resulting in a seizure. These malfunctions may include problems with sodium channels, calcium
channels, or with cell to cell interactions. Also, ensemble interactions play a role. Currently,
there are various treatments which include medication, diet, surgery, and also an implantable
device.
Other pertinent issues with epilepsy deal with social aspects. Sexual dysfunction is
prevalent in epileptics. Epileptic women need to be aware of fertility problems. In addition,
catamenial epilepsy affects many epileptic women. Pregnancy difficulties result both from the
seizures themselves and from the teratogenicity of the medications. Sudden, unexplained death is
also prevalent in epileptics. Also, memory problems are often associated with this condition. In
addition, medication costs can plague epileptics.
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Mechanisms of Epileptic Seizures
Epilepsy is the most common neurological disorder. It is presumed to affect from
one half of one percent to one percent of the population. Epilepsy is a broad diagnosis for
a number of neurological misfunctions that manifest themselves as different types of
seizures. This chapter explores the possible causes of seizures.
Epileptic seizure can be characterized by two primary features, both of which are
sufficient to produce seizure activity by themselves. The first is hyperexcitability of
multiple neurons within a population. As will be shown, most of the means to produce
this effect are normal basic mechanisms that have been deregulated.

The second is

hypersynchrony. Petit mal epilepsy is a common example of a clinical syndrome in
which epilitiform activity involves primarily hypersynchonization.

The abnormal

discharge appears to result from a synchrony of widespread cell populations so great as to
wipe out any functionally significant signals that might enter the central nervous system.!
An important component of the nervous system is its plasticity, the basic
mechanism

that

supports

change.

However,

this

component

can

hyperexcitability and hypersynchrony that characterize epileptiform activities.

produce
Brain

regions, such as the cortical structures, with best preparedness for plastic responses are
most likely to be the focus of epileptiform activity. Three contributions to epilepsy's
irregular neuronal function are intrinsic cell properties, cell-to-cell interactions, and
ensemble interactions. 2
There is great debate over whether there are "epileptic neurons" in populations of
cells. These neurons were thought to be cells with "intrinsic abnormalities that drove the
activity of normal neurons."3

No cells with such qualities have been located by

researchers. However, scientists feel that there must be some abnormality at the singlecell level. Because many factors influence the cell's excitability, isolation in a research
environment can show little evidence of being intrinsically epileptic. 4
In the electronic structure of the molecule, recent studies have shown that

synapses located closer to the initial segment have more powerful effects than synapses at
more distant processes. This demonstration has caused much optimism in the field of
neurology because the epileptic brain's cells may only have proximal dendrites. This
structural change could contribute significantly to altering the transfer of synaptic current.
In instances of abnormal increased activity, a small morphologic alteration has been

found by researchers. This change could quite possibly explain the positive feedback that
most epileptics experience. 5
The depolarization of the membrane causes the opening of the sodium channel.
This depolarization forms the upstroke of the action potential. These channels inactivate
quickly and then no longer allow ionic flux.

Thus when a neuron is significantly

depolarized, spiking may quickly fade away. Repetition of discharge is critical to a cell's
abiltiy to participate in an aggregate of hyperexcitable neurons. 6
In addition to this inactivating sodium current, a noninactivating sodium current

has been found in many pyramidal neurons. Opening of this channel occurs with only
small amounts of depolarization (from resting potential), and the current contributes in
subtle, but important ways to the pattern of cell activity. For example, if the excitatory
postsyanptic potential (EPSP)-induced depolarization is sufficient to open the
noninactivating sodium channels, the depolarization booster mechanism is relatively

2

long-lasting because the current is noninactivating, and may be sufficient to bring
subthreshold depolarizations to a suprathreshold level to initiate spike discharge.?
Calcium channels are divided into three categories. The first, the T -type channel,
is considered low-threshold and is thought to help to synchronize cell populations. This
channel can cause a burst of action potentials when it opens to admit calcium. This
opening will further depolarize the cell. Some Petit mal seizures have been known to
originate in deformities at these channels. 8
Another type of calcium channel (L-type) remains closed at resting potential. It
opens when the cell is depolarized by a great number of millivolts.

The voltage-

dependent calcium influx may add significantly to the depolarization. Summation can
generate the burst discharges.

The final channel is the N-type, whose role in the

postsynaptic cell is unclear. 9
Neurotransmitter is dependent on the voltage-dependent conductance in terminal
membrane. N-type calcium channels contribute to the calcium influx while potassium
repolarizes the cell membrane to prevent too much calcium from entering. The level and
pattern of activity in single elements of a large interconnected population significantly
affect the pattern of discharge in the population as a whole. Therefore, the epileptiform
discharge is more likely when there is an increase in the level of excitability at the singlecell level, like in cases of spontaneous excitatory transmitter release. IO
Cell-to-cell interaction can range from chemical transmission to ephaptic
interaction. Modification of either of these activities can result in epileptogenesis. The
loss of GABAergic inhibition is the foundation for a long held hypothesis in epileptiform
activity. GABA is the primary inhibitory neurotransmitter in cortical structures. GABA-

3

a receptors mediate the inhibitory postsynaptic potentials (IPSPs). Binding of GABA to
this receptor leads to the opening of chloride channels, causing hyperpolarization.
However, because the voltage change depends on the resting potential, GABA might in
fact cause depolarization.

The GABA-b receptor is linked to a potassium channel

through a guanosine triphosphate binding protein. The hyperpolarization accompanying
this receptor is slow and long lasting. In the presence of moderate GABA-a blockade, the
GABA-b mechanism successfully modulates duration of burst discharge. GABA release
from interneuron terminals may be reduced by activation of GABA-b presynaptic
receptors. I I
Glutamate has long been recognized as the pnmary candidate for
mediating fast excitatory synaptic transmission in the cortex and the hippocampus. Many
glutamate-receptor SUbtypes exist.

The primary iontropic receptors (those associated

directly with an ion pore) form two major subdivisions, NMDA-preferring receptors and
non-NMDA receptors.l2
On most occasions, excitatory postsynaptic potentials in cortical structures are
produced mainly through activation of non-NMDA receptors. When this channel opens,
it is permeated primarily with sodium and potassium ions. The NMDA receptor is more
like GABA-a receptor in its complexity and various sites of modulation. This channel is
voltage sensitive, being normally blocked by magnesium that binds to a site inside the
channel. This magnesium blockade is relieved by cell depolarization, as may occur when
excitatory synaptic input (mediated by non-NMDA receptors) depolarizes the membrane.
Glutamate binds to the NMDA receptor then opens a channel that is permeable to both
sodium and calcium. Calcium influx through NMDA channels triggers a number of

4

important processes. Long-term potentiation can be initiated by calcium influx through
NMDA channels. 13
The involvement of NMDA in epileptogenesis is suggested by findings of an
enhanced NMDA component in the EPSP onto hippocampal neurons in kindled tissue
and by significant NMDA contributions to EPSP's recorded in human epileptic cortical
and hippocampal neurons. In addition to their voltage and magnesium control, NMDA
receptors are modulated by glycine (necessary for function), zinc (inhibitory), and
polyamines. As with the GABA-a receptor, NMDA receptors must be phosphorylated for
efficient function.

The potential importance of NMDA function is illustrated by the

efficacy of NMDA channel antagonists in blocking late components of burst discharge in
blocking late components of burst discharge in some models of epileptogenesis. The
NMDA antagonist amino phosphonovalerate potently blocks initiation but is ineffective
against already potentiated synaptic responses.

This fact suggests that the NMDA

mechanism is important in kindling of seizure development. 14
Cell loss is common in the epileptic brain. Glutamate receptors are also important
in mediating the cell damage so often associated with seizure discharge. Sclerosis is now
seen as a potential trigger for significant circuitry organization that could further increase
excitability. One proposed theory on cell loss is the calcium influx, mediated at least in
part by NMDA receptors, leads to destructive processes in some cells. The NMDA
antagonists can reduce or eliminate cell damage in ischemia or following high-frequency
electrical stimulation. Damage is cell-type specific that can explain the high density of
NMDA receptors on vulnerable neurons. Increases in intracellular calcium mediated by
NMDA receptors may initiate complex intracellular mechanisms, through second and

5

third messenger systems, that are aspects of normal as well as pathological cell function.
It has become clear that NMDA activation helps trigger complex changes in central
nervous system neurons. IS
Researchers are becoming more interested in other neurotransmitters as
mechanisms and actions are being discovered. Acetylcholine has long been known to
excite the central nervous system neurons. The muscarinic receptor actin is mediated by
a G-protein and generally involves slow changes in membrane potential (depolarizations)
and increased input resistance, primarily through blockade of a potassium current.
Similar effects occur with the application of noradrenergic beta-agonists. As a result of
the action of such drugs, cell firing during membrane depolarization shows less
adaptation, and hyperpolarizing afterpotentials are significantly reduced. Both effects
contribute to increased excitability.

However, the purpose of intrinsic cholinergic and

noradrenergic systems in epileptogenesis is not fully known. Other neurotransmitters
include somatostatin and cholecystokinin, neuropeptides with undetermined roles and
mechanisms. 16
Investigations have found that circuitry reorganization occurs as a result of
seizures in humans. This change involves "sprouting" of axon branches and terminals
that occur as a result of seizues in human and animal tissue. Sprouting has been seen as
concurrent loss of cells.

This evidence suggests that the sprouting axons "fill in"

at synaptic sites where cell death has removed the normal presynaptic element. The
granule cells themselves then expand their recurrent collateral field to occupy the vacated
synaptic space. 14

6

The excitability of the system could increase as a result of this reorganization
process which could cause recurrent additional excitatory feedback.

If inhibition is

blocked, the sprouted dentate can be shown to by hyperexcitable. Electrical transmission
does occur in the central nervous system.

These interactions are mediated by gap

junctions and are seen in both the hippocampus and the neocortex.

This coupling

provides a fast and secure means for synchronizing neuronal populations and could be
important in the development of synchrony in epileptogenesis. 17
Clearly not all hyperexcitability and hypersynchrony are the result of chemical
transmission between cells. Ephaptic interactions, which are defined as synchronizations
of cellular activity mediated by the flow of current through extracellular space, are
suspected to be involved in normal cell functioning and in maintaining epileptiform
activity in the absence of chemical transmission. Changes in extracellular space influence
current flow and extracellular ion concentrations. Chronically epileptic tissue has shown
that extracellular calcium concentration decreases during epileptiform bursting activity to
levels that can not maintain strong synaptic connectivity in the recruitment and
synchronization of cell discharge during seizures. IS
The role of glial is considered important in epileptogenesis.

Its function is

thought to be the uptake of potassium from the extracellular space to protect the neuronal
membranes and maintain appropriate levels of extracellular ion concentration.

Glial

infiltration into epileptic foci is common. This action is thought to be a response to high
level of activity, because no deficits in glial function have been found to contribute to
epilepsy. However, researchers have not ruled glial out because in some studies glia have
shown active properties, such as spiking activity.19

7

Ensemble interaction is an important aspect of epilepsy because of the function of
large populations of synchronously active neurons during epileptogenesis. If the seizure
has a focus, than the way its activity is transmitted from focus to follower region is very
important.

Several mechanisms have been discussed concerning how terminals are

excited. These include accumulation of extracellular potassium and release of excitatory
transmitter, which proceeds to depolarize terminals. The spread of hyperexcitability is
limited by the relationship of brain regions to activate those regions that they are
synaptically coupled to.

Another proposed mechanism is the accumulation of

extracellular potassium ions.

Potassium can be redistributed to other brain regions

through diffusion or by means of glia in a relatively nonspecific manner.

The

extracellular ion buildup may be involved in recruiting neighboring brain areas into the
hyperexcitability discharging region. Similarly, ephaptic interactions can recruit neurons
in increasingly wider areas of tissue into synchronized discharge, especially when field
potentials in the focal regions are large enough to reflect significant extracellular current
flow. 2o
One of the most recent concepts to come out of epilepsy research is that of
permissive gating, especially regarding the granule cells of the dentate gyrus. The dentate
is a relatively inexcitable part of the hippocampal formation, often generating normal
activity even in the face of highly abnormal discharge in CAl and CA3 regions. Maximal
activation of the dentate is now thought to be associated with seizure spread through
hippocampus and into other brain regions. It is ideally situated to play a gating role
because of the primary afferent input into the hippocampus is funneled through the
granule cells. Researchers have speculated that the substantia nigra pars reticulata is

8

critical in the generalization of seizure activity. Data suggests that blocking the output of
the nigra can curtail the development and spread of seizure activity. A similar gating role
has been postulated for thalamic regions and for superior colliculus. 21
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Treatments of Epilepsy

Given the relatively complex concepts about how and where seizure activity is generated,
the blockade of seizure activity can be accomplished in many ways, including anti epileptic drugs,
surgery, the ketogenic diet, a new device, and a rectal gel.
One family of medications includes phenytoin, valporic acid, and carbamazepine. These
drugs interfere with repetitive spiking activity by dampening pathogenic, activity of sodium
channels. The adverse effects of phenytoin include anorexia, nausea, vomiting, aggression, ataxia,
cognitive

impairment,

drowsiness,

depression,

headache,

and

paradoxical

seizures.4

Carbamazepine is used for partial and! or secondary generalized seizures. Sodium valporate is
used as a first line drug for partial and!or secondary generalized, generalized tonic clonic seizures
without other seizure types, typical absence, myoclonic absence, atonic, tonic and most childhood
absence seizure types. Carbamazepine has adverse effects including diploia, dizziness, sedation,
and induction of liver enzymes.4
Ethosuximide, trimethadione, and methosuximide appears to target low threshold calcium
specifically, acting preferentially on cells whose activation pattern depends predominantly on
these channels. Ethosuximide, another antiepileptic drug used specifically for petit mal epilepsy,
acts on this channel to prevent a rise of a burst of action ~otentials that can develop when these
channels open to admit calcium. (other book) The thalmic role in producing spontaneous rhythmic
activity, dependent on low threshold calcium conductances, is believed to be specifically

antagonized by such drugs.
Tiagabine and vigabatrin enhance cerebrospinal levels of GAB A by interfering with
reuptake and degradation of GABA, respectively.1 Tiagabine has been deemed effective in partial
and secondarily generalized seizures. The adverse effects of Tiagabine include dizziness, asthenia,
and tremor. 2

Vigabatrin is not limited to partial seizures.

first-choice AED against infantile spasms.

It has emerged as a potential

The most common adverse effects of vigabatrin

include drowsiness, dizziness, ataxia, tremor, amnesia, depression, weight gain, and hyperactivity
in children. Recently visual field constriction, bilateral optic disc pallor, and subtle peripheral
retinal atrophy have been linked to vigabatrin.2
Lamotrigine, like phenytoin and carbamazepine, blocks sodium channels. 1 This sodium
channel blockade results in inhibition of glutamate release. There is increasing evidence that
lamotrigine is effective against generalized seizures, particularly absence seizures.2 Some of the
most common dose-related adverse effects include dizziness, sedation, headache, diplopia, and
ataxia.2
Another antiepileptic medication is Gabapentin. It is the first AED to be eliminated
entirely by the kidneys.2

Gabapentin is designed as a centrally acting GABA agonist, yet it

apparently does not interact with GABA receptors nor does it interfere with GABA metabolism.
It instead interacts with a novel binding site, which contains a specific protein found only on
neurons in the central nervous system. This protein is found in highest density in areas of the

neocortex that are rich in synapses containing the excitatory neurotransmitter glutamine.1
Adverse effects of gabapentin include somnolence, dizziness, ataxia, behavioral problems, weight
gain, and movement disorders. Serious adverse events have been exceedingly rare?
Topiramate has been identified as having at least three mechanisms of action. These
include state-dependent blockade of sodium channels, potentiation of gamma-aminobutyric
acid-mediated neuroinhibition, and blockade of glutamate-mediated neuroexcitation. This drug is
effective in refractory partial seizures in adults, partial seizures in children, and generalized
tonic-clonic seizures in children and adults. The most common adverse efects of topiramate
include sedation, problem with concentration and word finding, decreased appetite, and weight
loss. Nephrolithiasis has occurred in 1.5% ofpatients. 2
Surgery is gaining increasing popularity as a method of treating patients who have focal
seizures unresponsive to anti convulsant therapy. EEG recording with videotaping is important in
localizing the site. Subdural electrodes are often used to determine the extent of the epileptogenic
activity accurately. Other tests are used to assist in localization of seizure foci . These include
neuropsychologic evaluations, the Wad a test, SPECT, PET, and MRI studies. Temporal lobe
resection is the most common surgery performed.2 Although not always successful, surgery can
relieve patients of the burden of medication and general dysfunction.
The ketogenic diet was frequently used for the treatment of intractable epilepsy before the
discovery of the newer antiepileptic medications. The mode of action is unknown, but the seizure

control may be correlated directly with elevated levels of beta-hydroxybutyrate and acetoacetate
that result from ketosis. 3 The ketogenic diet supposedly simulates the metabolism of a fasting
body, which has been considered since biblical times an effective means to control seizures. This
fast was then coupled with a high-fat diet in order to cause acidosis, ketosis, and increased levels
of uric acid levels in the blood and urine without causing starvation.4
On July 16, 1997, the US Food and Drug Administration approved the first implantable
device to reduce the number of seizures. It is seen as the pacemaker for the vagus nerve, whose
stimulation produces an anti-epileptic effect by modulating the abnormal neuronal firing
associated with seizures. When implanted, the device not only provides stimulation to the vagus
nerve at regular intervals, but the patient also has a magnet that can stimulate the nerve at the
onset of a seizure. The device is well tolerated and accepted by patients.
In July of 1997, Diastat was approved by the FDA. This drug is a gel formulation for
rectal administration of the antiepileptic diazepam to stop clustered or prolonged seizures in
progress. It is the first therapy prepared to be easily given in this manner ever to become
available for in-home use in bringing potentially dangerous bouts of increased seizure activity
under control. This drug will be able to give caregivers a greater sense of control. Trips to the
emergency room are able to be greatly eliminated during bouts of unstoppable seizures.
Somnolence and headaches were the tow most frequently reported side effects in these studies. 3
Epilepsy research is at a fast pace. Therefore, as more is learned about the functions, and

malfunctions, of the brain, more is done in developing mediations designed to fit specific problems
and patients. These newer medications are generally better tolerated by patients as they have
fewer side effects. However, because of ethical obligations in test design, most new medications
are only approved for add-on therapy.

Neurologists, researchers, and patients all remain all

remain hopefully that one day all epileptics will be able to say that they are seizure-free.
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Sexuality in Epilepsy

Sexual behavior requires a normally functioning neuroanatomic substrate, which includes
the frontal lobe and limbic structures, as well as adequate levels of hypothalamic, pituitary, and
gonadal hormones. This behavior can be disturbed in epilepsy.1
Sexual behavior can be divided into two main components, desire and arousal. Desire
reflects the individual's psychological heath, cultural expectations, past sexual experiences, and
requires salient sexual stimuli.

Hormones are also required to support sexual desire. Those

hormones include estrogen, progesterone, testosterone, lutenizing hormone, follicle stimulating
hormone, and prolactin.2
Arousal is defined as the ability to respond to an appropriate stimuli with a series of
stereotyped vascular, neural, and muscular responses. A normal sexual response requires an
intact, functioning cerebral cortex, spinal cord, and autonomic nervous system. Genital structures
must be normal. Hormones also play an important role.3
Sexual dysfunction was first described in people with epilepsy in 1956. Thirty to sixty
percent of men with epilepsy have some disorder of desire or arousal, most often impotence. In a
study conducted in 1985, 21 percent of men studied had never experienced sexual intercourse
despite having the opportunity to do so. Also, in this same study at least one third of sexually
active subjects had difficulty achieving and maintaining an erection or ejaculating.4
In epileptic women, there is a high incidence of dyspareunia, vaginismus, and arousal

insufficiency. One third of women described themselves as dissatisfied with their overall sexual
function, compared with eight percent of the normal population.S
There are a number of potential mechanisms by which sexuality may be disturbed in
people with epilepsy. Psychosocial deficits, such as restricted social opportunities and poor
self-esteem, limit the opportunity for normal sexual interactions. Poor disease acceptance is
associated with sexual dysfunction in other chronic illnesses, and may contribute to impaired
sexuality in epilepsy.

However physiological mechanisms may be more relevant than

psychological variables. Disruption of cortical regions mediating sexual behavior, either by fixed
lesions or by epileptiform discharges, could influence sexual desire and arousal.

Changes in

hormones supporting sexual behavior occur in epilepsy, both because of seizures and antiepileptic
drugs. Antiepileptic drugs have direct effects on conical regions mediating sexuality and may also
cause sexual dysfunction by secondary effects on reproductive hormones.6
Psychosocial disability can adversely impact sexuality in men and women with epilepsy.
Individuals with epilepsy are susceptible to poor self-esteem. Recurrent seizures may lead to a
sense of vulnerability and helplessness, impairing the capacity to form healthy, nurturing
relationships.

Having epilepsy may limit social development, particularly for patients with

frequent seizures who have restricted access to usual educational and occupational experiences.
Individuals also express concern that sexual activity will precipitate a seizure, particularly those
whose seizures are sometimes triggered by hyperventilation or physical exertion.?

Several clinical observations suggest that dysfuntion in limbic structures predisposes to
sexual dysfunction. Sexual dysfunction usually arises after the onset of seizures. It is most
common in individuals with localization-related epilepsy, particularly those whose seizures arise
from the amygdala and hippocampus. Reports show that sexual dysfunction improves after
temporal lobectomy for medically intractable seizures. 8
Alterations in pituitary and gonadal hormones can negatively impact sexual behavior in
people with epilepsy. In both epileptic men and women, interictallevels of prolactin are elevated
because of seizures. Elevated prolactin is one of the most frequent causes of impotence in
otherwise healthy males. The free fraction of sex steroid hormones may be reduced in individuals
with epilepsy. Low levels of free testosterone have been associated with disorders of sexual
desire and ,amusaLin men.9
Sexual dysfunction may also be a consequence of ictal alterations in neurotransmitters,
including gamma amino-butyric acid (GABA), opioids and serotonin. In a study using rabbits,
elevations in GABA inhibit sexual behavior. Serotonin agonists specific to one receptor subtype
inhibit sexual desire and sexual arousal in rats.10
Antiepileptic drugs affect sexual behavior by at least two mechanisms-alterations in
hormone metabolism and binding, and by direct cortical effects. They may induce or inhibit the
hepatic microsomal enzyme system and alter metabolism of sex steroid hormones.

Many

antiepileptic drugs also induce production of sex hormone binding globulin (sHBG), a binding

protein for steroid hormones. Increased binding reduces the free, biologically active traction.
These two mechanisms cause a reduction in the free level of steroid hormones. Antiepileptic

drugs are also associated with elevations in prolactin and gonadotropins. Antiepileptic drugs may
act as suppressants of sexual behavior. Diminished libido and arousal were described in 12% of
men beginning an antiepileptic drug.11
AED's do not cause all sexual deficits observed in people with epilepsy. First, sexual
dysfunction generally arose with the onset of epilepsy- prior to treatment. Sexual deficits may
improve when seizures are controlled, even if a higher dose of antiepileptic drug is required or a
temporal lobectomy is performed.12
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Fertility Problems in Epilepsy

Women with epilepsy have fewer children than women in the general population. Their
fertility rate is 25 to 33 percent lower than the average. Social pressures on women with epilepsy
to refrain from having children may be a factor in their lower rate of childbearing. However,
studies reveal that biological factors rather than social factors play a role in the higher rates of
infertility in women with epilepsy.l
Menstrual irregularities are seen more often in women with epilepsy than in women who
do not have the disorder. Research has demonstrated a high proportion of reproductive and
endocrine disorders in women with epilepsy, which can affect their ability to conceive or carry a
child to term.2
Menstrual abnormalities and gynecologic syndromes such as polycistic ovaries,
hypogonadotropic and hypergonadotropic hypogonadism, oligomenorrhea, and amenorrhea are
more common in women with epilepsy. A probable cause for this is the effect of antiepileptic
mediation on the hypotharnic-pituitary axis, or indirectly through alterations in the metabolism of
sex steroids.

Women with temporal lobe epilepsy are particularly prone to anovulation.

Dysfunction of the limbic cortex, which is extensively interconnected with the hypothalamus,
appears to alter the release of hypothalrnic hormones and pituitary gonadotropins, resulting in
anovulation.3
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Catamenial Epilepsy

Catamenial epilepsy is defined as a cyclic increase in epileptic attacks which coincide with
menses. In early times, these changes were attributed to the moon. In 1885, Gowers first
examined the association of menses and epilepsy.1
Catamenial epilepsy is observed in 10 to 70% of women with epilepsy. This wide range in
incidence is due to the lack of a more specific definition of catamenial epilepsy. 70% of women
claim that their seizures are exacerbated by menstruation. However, the strict definition states
that catamenial epilepsy is epilepsy that occurs at or worsens around menstruation, and can be
demonstrated in 12% of women with epilepsy. These menstrual exacerbations occur with all
types of seizures.2
Several investigators show that even nonepileptic women exhibit minor EEG fluctuations
during the menstrual cycle.

In 1942, Dusser de Barenne and Gibbs discovered cyclical

background slowing during two menstrual phases: the time of menstrual flow and the time of
ovulation. Other studies reveal a drop in the amplitude of the EEG during the premenstrual and
menstrual phases.3
Catamenial epilepsy is believed to result from cyclic alterations in both ovarian hormone
levels and drug metabolism. In women with catamenial epilepsy, seizures frequently start at or
shortly after menarche. Many of these women show increased electroencephalographic activity
during menstruation. Seizure threshold is increased by progesterone and decreased by estrogen,

an effect presumably caused by alterations in brain excitability. Frequency of seizure activity has
been shown to increase during two specific times in the menstrual cycle. The first corresponds to
the rapid decrease in progesterone just before menses and the second to the elevation of estrogen
before ovulation.

An increase in frequency is also seen during anovulatory cycles when

progesterone levels are relatively low. Menopause or oophorectomy may lead to significant
improvement in epilepsy.4
Pregnanolone, a main metabolite of progesterone, modulates the major inhibitory
neurotransmitter, gamma-aminobutyric acid (GABA), and augments the GABA-induced chloride
current in hippocampal neurons. It is hypothesized that endogenous neurosteroids including
pregnanolone, may decrease when progesterone concentrations fall before menstruation, reducing
the inhibitory effets of GABA and causing seizure exacerbation.5
A 1986 study by Rosciszewska, Bunter, Guz, and Zawisza showed that seizure incidence
during the menstrual cycle is connected with a deficit of progesterone rather than elevated
oestrogen levels. In the study, the lowest number of seizures was noted when progesterone
reached its highest level. The "protective effect" of progesterone on brain activity in women can
be confirmed by the use of synthetic progesterone in the therapy for catamenial epilepsy. A
related study showed

a reuction of seizure frequency in 7 of 10 women treated with

medroxyprogesterone.6
Females with so-called catamenial epilepsy had premenstual tension more frequently. This

difference is connected with greater endocrine disturbances and changes in water-electrolyte
balance. Thus, the effect of this syndrome on serum concentration of anticonvulsants during
premenstrual phase can not be neglected.7
A new controversy has erupted on the radical remedy of bilateral oophorectomy in order
to treat catamenial epilepsy. It is seen as a last result in patients with epilepsy that can not be
controlled by any of the appropriate and accepted treatments. A case in Liverpool studied a
woman who had tried hormonal treatment, regular anti epileptic drug treatment, and combination
anti epileptic drug treatment. When she became pregnant, she experienced no seizures until after
delivery.

Finally a total abdominal hysterectomy and bilateral salpingooophorectomy was

performed. She has had no seizures since the surgery.g Other doctors argue that this treatment
was too radical. They believe that epilepsy should be fully identified by the specific syndrome
and have the accepted treament possibilities exhausted before these unsubstantiated remedies are
used.9
Menstrual abnormalities and gynecologic syndromes such as polycystic ovaries,
hypogonadotropic and hypergonadotropic hypogonadism, oligomenorrhea, and amenorrhea are
more common in women with epilepsy. A probable cause for this is the effect of antiepileptic
medication pn the hypothamic-pituitary axis, or indirectly through alterations in the metabolism of
sex steroids.

Women with temporal lobe epilepsy are particularly prone to anovulation.

Dysfunction of the limbic cortex, which is extensively interconnected with the hypothalamus,

appears to alter the release of hypothalmic hormones and pituitary

gonadotropins~

resulting in

anovulation.10
Medication levels are known to fluctuate at different times throughout the cycle.
Decreased serum levels of phenytoin demonstrated during menses in women with catamenial
epilepsy correlate with increased seizure activity. "The decrease in estrogen and progesterone at
menstruation is believed to stimulate the release of hepatic monoxygenase enzymes which
accelerates the risk" of seizures.

Recommended treatment of catamenial epilepsy includes

measurement of serum levels of anticonvulsants during times of seizure exacerbation. Sometimes
an altered dosing schedule is recommended for seizure control. I I
Some investigations have shown that progesterone therapy is beneficial. In addition to
antiepileptic properties, progesterone may work by suppressing gonadotropin release

whic~

in

tum, lowers estrogen levels. The effects of combined oral contraceptives on frequency of seizure
have been inconsistent, with seizure exacerbation occurring on pill free days. Uninterrupted
combined use of oral contraceptives or the progestin-only oral contraceptive may be preferable in
women with epilepsy as they result in continuous progestin exposure. Because of the decrease of
efficacy of oral contraceptives in patients with epilepsy receiving anti-convulsant therapy due to
altered metabolism of the contraceptive steroids, a higher dose of oral contraceptive pills are
recommended.12
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Epilepsy and Pregnancy

Pregnancy in epileptic women is a growing concern in society. Women with epilepsy who
become pregnant are frequently considered to have a high risk of an adverse outcome.1
Congenital abnormalities are increased two to three times over the normal population.2 Not only
are the seizures themselves harmful to the child, but also the anti-epileptic drugs, AED's, prove a
threat to the child. Nekane et al., 1980, studied the incidence of newborn malformations born to
epileptic women. The study revealed that congenital malformations were least in newborns of
women not taking medication, but remaining seizure free. The highest prevalence was among
women who both had seizures and took AED's. Women having seizures but not taking medicine
and women without seizures but taking medication occupied an intermediate position. In addition
to the seizures and the medication, the changing metabolism of the mother can prove challenging
to the doctor. 3
Many women experience changes in drug metabolism during pregnancy. 25-30% of
women experience an increase in seizure frequency and severity during pregnancy.4 Because
there is an increase in circulating serum proteins, a decrease occurs in the blood level of free,
active drug. Therefore, physicians recommend that the free rather than total, serum drug level
should be monitored in pregnant patients.

The normal increase in extracellular fluid may also

cause fluctuations in antiepileptic drug levels. Other factors that may suppress drug levels are
delayed gastric emptying and hyperemesis. Physicians also cite noncompliance with medications,
hyperventilation, dilutional hypocalcemia and hyponatremia, emotional stress and sleep

deprivation as factors contributing to seizure frequency and intensity increases.5
The seizure itself can be harmful during pregnancy. A tonic-clonic seizure can result in
blunt abdominal trauma often causing premature rupture of membranes.6 These seizures have also
caused fetal intra-cranial hemorrhage, miscarriage, fetal neonatal, and prenatal death.7 Also, fetal
heart rate decreases during a seizure. If the mother has a seizure in the first trimester there is an
increased rate of spontaneous miscarriage and an increased risk in fetal malformations. These
effects are likely due to transient fetal hypoxia and acidosis secondary to altered uteroplacental
circulation.8
A decrease in fetal viability is seen in children of epileptic mothers. These infants are also
more likely to have lower Apgar scores. A decrese in fetal growth is also apparent in infants of
epileptics. These children are more likely to be small for gestational age. Seven to ten percent
meet the criteria for low birth weight. Also four to eleven percent are born premature.9

An increased risk offetal bleeding is seen in children exposed to AED's in utero.
Phenytoin, primodine, and phenobarbital are known to inhibit transport of vitamin K across the
placenta. Therefore, there is a decrease in fetal vitamin K-dependent clotting factors (II, VII, IX,
X). Fetal hemorrhage within 24 hours after birth is a probable outcome. Treatment for these

infants includes additional vitamin K, and fresh frozen plasma to correct the coagulopathy.lo
Scientists have targeted AED's as having teratogenic effects. All AED's have been found
to be teratogenitic.11 The greatest risk of congenital malformation comes with exposure to AED's

during the third to eighth week after conception.12 Minor digital and rnidfacial abnormalities are
seen in 5-30% of infants of women with epilepsy.13 Other malformations include neural tube
defects and heart defects.14 Polytherapy and higher drug levels are associated with an increased
risk of malformations.15 Cardiac defects are linked to phenobarbital, phenytoin, and primodine.
Trimethodione is not recommended for a pregnant mother because it produces severe birth
defects, mental retardation, and developmental delay in about 50% of offspring. 16
Of all the AED's, the hydantoins are most commonly associated with adverse pregnancy
outcomes. Approximately 1 in 500 pregnancies have had fetal exposure to phenytoin, the most
common hydantoin.

Fetal hydantoin syndrome occurs in 10-30% of exposed pregnancies.

Common symptoms of the syndrome include growth deficiency, central nervous system
dysfunction (e.g., mental retardation), craniofacial anomalies, increased risk of major
malformations and nail/digit hypoplasia. School and learning problems, developmental problems,
and physical abnormalities, such as nail hypoplasia and growth failure, are significantly higher in
those affected by the syndrome.

Increased risk for recurrence in subsequent pregnancies is

shown by studying families with two exposed children. In this study, either both or neither were
affected. Children exposed to phenytoin had an average global intelligence quotient (IQ) 10
points lower than controls.17
Carbamazepine is another AED shown to have teratogenicity. In one study 50 women
took carbamazepine as monotherapy.

35 gave birth to exposed infants with the following

abnormalities: craniofacial defects (11%), fingernail hypoplasia (26%), and developmental delay
(20%).

The syndrome causing these results was named "fetal carbamazepine syndrome" .

Children with this syndrome also exhibit slow development and low IQ scores. In a dosage study,
carbamazepine given at the highest dosage caused a significant decrease in fetal body weight, a
2.9-fold increase in fetal resorptions, and a 29% decrease in maternal weight compared to
controls. Soft tissue and skeletal malformations increase sixfold. 18
Valporic Acid, VP A, also has teratogenic effects. It has been linked to spina bifida with a
1-2% risk with maternal use. Fetal valparoate syndrome has been described. Symptoms include
craniofacial anomalies, with minor abnormalities in ear shape or position being common,
congenital heart defects. Developmental delay occurs in more than two-thirds of the cases
exposed to monotherapy. Recently it has been reported that neurologic performance is still
impaired at 6 years of age.19
Fetal benzodiazepine syndrome is frequent in children born to mothers taking
benzodiazepines. Frequent symptoms include short nose with a low nasal bridge, and uptilted
nose and epicanthic folds . Other symptoms include slanting eyes, low-set or abnormal ears, and a
hypoplastic mandible. Children also had delayed neurodevelopment. Infants exposed to both
VP A and benzodiazepines had more pronounced abnormalities than those receiving monotherapy.
In one study, 64 out of.80 infants receivin~ benzodiazepines in utero had sedation and withdrawal
symptoms at birth. Fifty had no developmental anomalies, but 6 had conditions consistent with

teratogenicity.20
Primo dine and phenobarbital are associated with fetal anomalies similar to those
associated with other AED's.

Symptoms include both pre- and postnatal growth failure,

hirsutism, microcephaly, mental retardation, hypoplastic nails, and craniofacial anomalies such as
short nose, ptosis of the eyelids, low-set ears, and CP.

Prenatal exposure to phenobarbital

exposure has been shown to lower verbal inteligence score in adult men tested in a recent study.21
Trimethadione is contraindicated in pregnancy. It produces severe birth defects, mental
retardation, and developmental delay in fifty percent of offspring.

Therefore, a woman of

childbearing age should not take trimethadionine.22
The teratogenicity of the newer antiepileptic drugs are not well documented. However,
some information is obtained by the preclinical studies. Felbamate did not show birth defects in
rats or rabbits. Gabapentin at high doses was toxic to rodent fetuses . Delayed ossification of
bones was also noticed. Lamotrigine is a weak inhibitor of dihydrofolate reductase, and antifolate
activity is associated with teratogenicity.

Topoiramate showed growth retardation and limb

agenesis. Tigabine has shown growth retardation in animal studies.23
The risk of the child of an epileptic having epilepsy is increased to two to four percent
compared with one percent for the general population. Also a significant risk of fetal death is
present, although this risk has been minimized with the growth of knowledge on the subject.
Sedation may occur in the infant if it injests phenobarbital from breast feeding. Most mothers

taking AED's can breast feed .24 However, phenobarbital or primidone should be used with
caution by nursing women. Women taking gabapentin, topiramate, or tiagabine should nurse only
when the benefits outweigh the risks. Mothers taking lamotrigine are not recommended to breast
feed. The manufacturer of felbamate suggests it be used with caution in nursing women.2S
Multiple antiepileptic drugs have been shown to increase risk profiles. "When
carbamazepine, phenobarbital, and VPS are combined with or without phenytoin, 58% of infants
have birth defects. ,,26 This is higher than with outher three- to four-drug combinations, suggesting
metabolic interactions.

VP A inhibits epoxide hydroxylase, which increases the presence of

epoxide metabolites of aromatic AED's.
Maternal folate concentrations normally decline during pregnancy. AED use may cause
further decreases, thereby increasing the risk of folate deficiency. In one study, phenytoin and
phenobarbital produced the greatest decrease in serum folate.

Serum folate and RBC folate

concentrations were significantly lower in women having spontaneous abortions or children with
major malformations compared with those with normal outcomes.

Pregnant women taking

multiple anticonvulsants tended to have an increased risk for folate deficiency compared with
those receiving monotherapy. Women were more likely to have an adverse pregnancy outcome
when serum folate was less than 4 microgram! mL before pregnancy.27 Phenytoin, carbamazepine,
phenobarbital, lamotrigine, and possibly valporate have been found to have antifolate activity.28
Findings in multiple studies showed that all women taking AED's should also receive

supplemental folic acid. 29
Oral contraceptives reduce both serum folate and RBC folate levels. Serum folate
concentrations decr~ase with chronic use of oral contraceptives and normalize within 3 months
after discontinuing the oral contraceptive. Epileptic women taking oral contraceptives and AED's
may be at higher risk, since they are taking more than one folate-lowering drug, and may
experience contraceptive failure caused by enzyme-inducing AEDs. More studies are needed in
order to see the true effects.30
Reactive epoxide metabolites may be responsible for AED-induced teratogenicity.
Phenytoin, carbamazepine, phenobarbital, felbamate, and lamotrigine may be metabolized to form
epoxides. Adding valporic acid to any of these AED's may increase the risk, because this drug
inhibits epoxide hydrolase, thereby increasing epoxide concentrations. Folate deficiency could
further increase epoxide concentrations of aromatic AED's.3\

AED's may be particularly

dangerous in women predisposed to give birth to infants with neural tube defects. These women
may not utilize folate as efficiently as other women and AED use diminishes serum folate
concentrations.32
Physician recommendations for epileptic mothers include the following:
1. Use a first-choice antiepileptic drug for seizure type and epilepsy syndrome.
2. Use the AED as monotherapy and at the lowest dose possible that protects against

tonic-clonic seizures.

3. Monitor plasma AED levels monthly and, if possible, obtain free or unbound levels.
4. Avoid polytherapy, especially combinations of valpro ate, phenobarbital and
carbamazepine.

5. Avoid valporate and carbamazepine when there is a family history of neural tube
defects.
6. Begin folate supplementation in the preconception period.
7. When using valporate, avoid high plasma levels and divide the dose over three to four
administrations per day.33
In addition to the above, physicians often recommend women delaying pregnancy until

seizures are adequately controlled. Also, amniocentesis and level II ultrasound at 16-18 weeks
should be preformed to check for neural tube and cardiac malformations. Vitamin K should be
given to mother from her 36th week on and also given to the baby at birth. 34 Some physicians
also recommend a gradual discontinuation of antiepileptic drugs if a woman is seizure-free with a
normal encephalogram for at least two years.35
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Sudden Death and Epilepsy
Sudden unexpected, unexplained death (SUD) is more common in patients with epilepsy
compared with the general population. The mechanism is unclear, but there are several theories.
These include cardiac tachy- or bradyarrhythmias related to paroxysmal autonomic dysfunction,
respiratory arrest and neurogenic pulmonary oedema, and events occuring in connection with
overt or subclinical seizures.

Low or undetectable post-mortem blood concentrations of

antiepileptic drugs has been a frequent finding in cases of SUD. Although these reports have been
questioned based on their methodology, they have raised questions regarding sudden drug
withdrawal or non-compliance as precipitating factors for SUD.I
The anitepileptic drugs carbamazepine and phenytoin are sodium-channel blockers with a
membrane stabilizing effect in the central nervous system as well as in the cardiac conduction
system and myocardium. Carbamazepine may induce cardiac bradyarrhythmias, which has caused
safety concerns, and phenytoin has been used and classified as an antiarrhythmic drug. A sudden
withdrawal of such cardioactive drugs might theoretically induce both direct and indirect cardiac
changes of relevance for SUD unrelated to seizure activity. 2
A recent study demonstrated that abrupt withdrawal of antiepileptic treatment reduced
heart-rate variability suggesting an altered autonomic modulation, which in other patient
populations has been associated with increased mortality. The withdrawal of these drugs induced
an expected reduction in bradycardias in a subgroup of patients. However, there was also an

unexpected 10-fold increase in ventricular premature beats in some patients suggesting increased
electrical instability. Since reduced heart-rate variability signals a state of increased electrical
vulnerability and ventricular premature beats might trigger life-threatening ventricular arrhythmias
the findings of the experiment point to two important factors that might contribute to an increased
risk for sudden death during abrupt withdrawal of sodium-channe1-blocking antiepileptic drugs
even in the absence of seizures. 3
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Memory and Epilepsy

Cognitive dysfunction has long been known to accompany seizure activity. There are
many different factors affecting memory. These include the underlying cause of the epilepsy,
seizure type, frequency and severity of seizures, undetected seizures, psychosocial factors such as
mood and expectations and anti epileptic drugs.1 It is agreed that memory function improves as
the control of seizure improves.2
Structural cerebral abnormalities which underlie the epileptic focus often directly cause
cognitive dysfunction. However, epileptic foci arising distant from those brain structures known
to be involved in learning and memory may also be associated with disorders of learning and
memory. Excision of epileptic foci was shown to improve cognitive function in experimental
models in primates.3
It appears that seizure activity incrementally causes an indiscriminate and widespread

induction of long-term potentiation, consuming and thereby reducinE overall hipJ>ocampal
plasticity available for information processing. Because the seizure activity appears to consume
the synaptic J>lastici~ available in otherwise healthy brain tissue making the formation of new
memories is disrupted, and may represent a mechanism by which cognitive function is impaired in
epileptic humans.4
The physiological and cognitive effects can be modulated by NMDA receptor-associated
channel blockade.

This suggests that future therapeutic strategies directed towards the

preservation of hippocampal synaptic plasticity may prove effective in the attenuation of
epilepsy-associated cognitive impairment. Unfortunately, presently available drugs active at the
NMDA receptor site (such as ketamine) can only be used effectively where seizure activity can be
precisely predicted, as in electroconvulsive therapy.S
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